Cend Therapeutics Announces First Patient Dosing in Clinical Trial of CEND-1 for the Treatment of Selected Gastrointestinal Cancers

Patient dosing has begun in a Phase Ib/IIa clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1, an investigational drug that modifies the tumor microenvironment, in pancreatic, appendiceal and colon cancers in collaboration with the University of Kansas Cancer Center.